Repligen Co. (NASDAQ:RGEN) Shares Bought by Wealth Alliance

Wealth Alliance lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 16.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,941 shares of the biotechnology company’s stock after buying an additional 277 shares during the period. Wealth Alliance’s holdings in Repligen were worth $349,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in RGEN. DekaBank Deutsche Girozentrale raised its stake in Repligen by 1.5% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company’s stock valued at $1,663,000 after acquiring an additional 159 shares in the last quarter. International Assets Investment Management LLC raised its stake in shares of Repligen by 18,449.1% during the fourth quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company’s stock valued at $10,539,000 after purchasing an additional 58,299 shares in the last quarter. American Century Companies Inc. grew its position in Repligen by 97.5% in the 3rd quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock valued at $34,648,000 after buying an additional 107,570 shares in the last quarter. Louisiana State Employees Retirement System acquired a new position in Repligen during the 4th quarter valued at about $2,625,000. Finally, Atria Investments Inc bought a new stake in shares of Repligen during the 3rd quarter worth about $1,046,000. 97.64% of the stock is owned by institutional investors.

Repligen Stock Performance

RGEN opened at $157.06 on Friday. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26. The firm has a market cap of $8.77 billion, a PE ratio of 218.14, a P/E/G ratio of 5.27 and a beta of 1.02. The business has a fifty day simple moving average of $190.02 and a 200-day simple moving average of $173.20. Repligen Co. has a fifty-two week low of $110.45 and a fifty-two week high of $211.13.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The business had revenue of $155.74 million during the quarter, compared to analyst estimates of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. Repligen’s revenue for the quarter was down 16.6% on a year-over-year basis. During the same quarter last year, the company posted $0.68 EPS. As a group, equities analysts predict that Repligen Co. will post 1.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on RGEN shares. KeyCorp raised their price objective on shares of Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Stifel Nicolaus lifted their price target on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $196.70.

Insiders Place Their Bets

In other news, Director Karen A. Dawes sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the sale, the director now owns 87,367 shares in the company, valued at $16,892,409.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Repligen news, COO James Bylund sold 4,373 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the sale, the chief operating officer now directly owns 14,135 shares in the company, valued at approximately $2,799,860.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the transaction, the director now directly owns 87,367 shares in the company, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Insiders sold a total of 25,597 shares of company stock worth $5,039,532 over the last ninety days. 1.20% of the stock is currently owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.